Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression
Autore:
Lepine, JP; Goger, J; Blashko, C; Probst, C; Moles, MF; Kosolowski, J; Scharfetter, B; Lane, RM;
Indirizzi:
Pfizer Inc, New York, NY 10017 USA Pfizer Inc New York NY USA 10017Pfizer Inc, New York, NY 10017 USA Univ Klin Psychiat, Graz, Austria Univ Klin Psychiat Graz AustriaUniv Klin Psychiat, Graz, Austria Centrecare St John Inc, New Brunswick, NJ USA Centrecare St John Inc New Brunswick NJ USA n Inc, New Brunswick, NJ USA Hop Fernand Widal, Paris, France Hop Fernand Widal Paris FranceHop Fernand Widal, Paris, France
Titolo Testata:
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 5, volume: 15, anno: 2000,
pagine: 263 - 271
SICI:
0268-1315(200009)15:5<263:ADSOTE>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
SEROTONIN REUPTAKE INHIBITORS; ANTIDEPRESSANT EFFICACY; HOSPITALIZED-PATIENTS; CONTROLLED TRIAL; MULTICENTER; PLACEBO; AMITRIPTYLINE; FLUVOXAMINE; PAROXETINE; ANXIETY;
Keywords:
clomipramine; endogenous depression; melancholia; sertraline; severe depression; sleep;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
40
Recensione:
Indirizzi per estratti:
Indirizzo: Lane, RM Pfizer Inc, 235 E 42nd St, New York, NY 10017 USA Pfizer Inc 235 E 42nd St New York NY USA 10017 York, NY 10017 USA
Citazione:
J.P. Lepine et al., "A double-blind study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression", INT CLIN PS, 15(5), 2000, pp. 263-271

Abstract

This study compared the efficacy and safety of the selective serotonin reuptake inhibitor sertraline with that of the tricyclic antidepressant clomipramine in patients with severe depression, as defined by a baseline 17-itemHamilton Depression Rating Scale (HAM-D) of at least 25. The study included 166 outpatients, randomized to double-blind treatment with sertraline (50-200 mg) or clomipramine (50-150 mg) for 8 weeks. The efficacy of both treatments was similar, 74% of patients in the sertraline group and 71% of clomipramine patients being classified as responders at the end-point, as defined by a Clinical Global Impression Improvement (CGI-I) score of 1 or 2. Mean HAM-D scores fell from 29.8 at baseline to 12.3 at endpoint in the sertraline group, and from 29.6-12.7 in the clomipramine group. There were more withdrawals due to adverse events in the clomipramine group than in the sertraline group (17% versus 12%). Dry mouth, tremor, dizziness and constipation were all substantially more common in the clomipramine group, whereas diarrhoea/loose stools was more common in the sertraline group. Overall, sertraline was as effective as clomipramine in this group of severely depressed outpatients, and showed better tolerability. (C) 2000 Lippincott Williams &Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 02:10:18